Vivos Therapeutics (NASDAQ:VVOS – Free Report) had its price objective upped by Ascendiant Capital Markets from $6.40 to $6.60 in a research note released on Tuesday morning, Marketbeat Ratings reports. The firm currently has a buy rating on the stock.
Vivos Therapeutics Price Performance
NASDAQ:VVOS opened at $2.71 on Tuesday. The firm has a market cap of $8.73 million, a price-to-earnings ratio of -0.25 and a beta of 7.74. The firm’s fifty day moving average price is $2.37 and its 200 day moving average price is $3.13. Vivos Therapeutics has a 1-year low of $1.91 and a 1-year high of $48.79.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Vivos Therapeutics stock. Armistice Capital LLC bought a new stake in Vivos Therapeutics, Inc. (NASDAQ:VVOS – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 57,000 shares of the company’s stock, valued at approximately $709,000. Armistice Capital LLC owned 4.29% of Vivos Therapeutics as of its most recent filing with the Securities & Exchange Commission. 26.35% of the stock is currently owned by institutional investors.
Vivos Therapeutics Company Profile
Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.
Featured Stories
- Five stocks we like better than Vivos Therapeutics
- What is the Hang Seng index?
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- What is the Shanghai Stock Exchange Composite Index?
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.